Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7192965 | 0.75 | AGTR1 (0.55) | HTR6AGTR1CXCL8NOD1SRC | |
| SCHEMBL12093313 | 0.71 | HTR6 (0.70) | HTR6ALDH1A1CXCL8NOD1SRC | |
| SCHEMBL13624636 | 0.70 | TP53 (0.56) | HTR6AGTR1 | |
| SCHEMBL19605706 | 0.66 | HTR6 (0.50) | HTR6AGTR1AVPR1ACXCL8NOD1 | |
| SCHEMBL3557485 | 0.66 | AGTR1 (0.58) | HTR6AGTR1CXCL8NOD1SRC | |
| SCHEMBL27885308 | 0.66 | ALKBH5 (0.51) | HTR6ALDH1A1AGTR1SRC | |
| SCHEMBL27885302 | 0.66 | HTR6 (0.50) | HTR6AGTR1SRCHTR1ADRD2 | |
| SCHEMBL20762057 | 0.65 | BRD4 (0.49) | HTR6AGTR1CXCL8NOD1SRC | |
| SCHEMBL30644289 | 0.65 | HTR6 (0.46) | HTR6AGTR1AVPR1ASRC | |
| SCHEMBL597369 | 0.65 | HTR6 (0.46) | HTR6AGTR1AVPR1ASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340548-B2 | Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors | Boehringer Ingehleim International GmbH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026162-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | HTR6 2018/4885ALDH1A1 1605/4885AGTR1 108/4885 |
| US-20150291592-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HAVCR2, CD4, HAX1 | HTR6 3755/4885ALDH1A1 773/4885AGTR1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.